PostEra Closes $24M in New Financing to Advance Drug Discovery - 12 January 2022 01:00

BOSTON, Jan. 11, 2022 /PRNewswire-AsiaNet/ -- PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced $24M in equity financing to accelerate medicinal chemistry and bring new cures to patients. Logo - https://mma.prnewswire.com/medi...

  Cambrex Celebrates its 40th Anniversary while Investing over $... - 12 January 2022 00:30

EAST RUTHERFORD, N.J., Jan. 11, 2022 /PRNewswire-AsiaNet/ -- Cambrex recently celebrated the 40th anniversary of its founding in 1981. Following forty years of growth and transformation into a leading global contract development and manufacturing organization (CDMO), Cambrex continues its commitment to lead...

  Gift of Life Donor Program Breaks National Records in Saving L... - 12 January 2022 00:05

PHILADELPHIA, Jan. 11, 2022 /PRNewswire-AsiaNet/ -- -- New CEO Richard Hasz Salutes Region – the Most Generous in the Nation for 14 Consecutive Years – and Team of "Heroes" for Extraordinary Commitment Gift of Life Donor Program ( https://c212.net/c/link/?t=0&l=en&o=3408741-1&h=3867576698&u=http...

  Clario and XingImaging expand partnership to deliver PET imagi... - 12 January 2022 00:00

BEIJING and PRINCETON, N.J., Jan. 11, 2022 /PRNewswire-AsiaNet/ -- Clario, a technology company that delivers the leading endpoint technology solutions for clinical trials, and XingImaging, a radiopharmaceutical production and positron emission tomography (PET) acquisition company, have expanded their partnership...

  Virtue Diagnostics closes $100 million Series B Funding - 06 January 2022 14:38

SHANGHAI, Jan. 6, 2022 /PRNewswire-AsiaNet/ -- Virtue Diagnostics, an innovative IVD company, has just announced closing US$100 million in Series B funding. Virtue Diagnostics, founded in 2019, is focused on clinical tests for China and emerging markets. Sequoia China and Morningside Ventures ...

  DiscGenics to Present at 40th Annual J.P. Morgan Healthcare Co... - 06 January 2022 12:05

SALT LAKE CITY, Jan. 6, 2022 /PRNewswire-AsiaNet/ -- DiscGenics ( https://c212.net/c/link/?t=0&l=en&o=3404974-1&h=3114304150&u=https%3A%2F%2Fwww.discgenics.com%2F&a=DiscGenics ), Inc., a privately held, clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies ...

  Tools4Patient Announces Name Change to Cognivia & Expands Boar... - 06 January 2022 02:00

MONT-SAINT-GUIBERT, Belgium, Jan. 6, 2022 /PRNewswire-AsiaNet/ -- Cognivia today announced a new name for the company formerly known as Tools4Patient, which provides clinical trials solutions based on AI / ML that account for individual patient personality traits, beliefs and perceptions. The transition to Cogni...

  COVID-19 Oral Vaccine and Antibody Booster: B. subtilis Spores... - 05 January 2022 13:00

HONG KONG, Jan. 5, 2022 /PRNewswire-AsiaNet/ -- Vaccines have been a trending topic ever since the coronavirus outbreak two years ago. DreamTec Research Limited (DreamTec, http://www.dreamtec.hk) has its major breakthrough in developing a COVID-19 oral vaccine. In its recently published peer-re...

  Breakthrough Discoveries on Novel Features of Omicron Variant ... - 04 January 2022 13:00

SHANGHAI, Jan. 4, 2022 /PRNewswire-Asianet/ -- Joint research results from Biologics of Jemincare and Shanghai Institute of Materia Medica (SIMM) of Chinese Academy of Sciences (CAS) confirmed that JMB2002, an anti-SARS-CoV-2 neutralizing antibody (NAb) discovered by Biologics of Jemincare is ...

  CStone Pharmaceuticals announced the IND approval of CS5001, a... - 03 January 2022 11:00

SUZHOU, China, Jan. 3, 2022 /PRNewswire-AsiaNet/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the investigationa...